Last reviewed · How we verify

Estetrol oral tablet — Competitive Intelligence Brief

Estetrol oral tablet (Estetrol oral tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor modulator (SERM). Area: Gynecology / Contraception / Women's Health.

phase 3 Selective estrogen receptor modulator (SERM) Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) Gynecology / Contraception / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

Estetrol oral tablet (Estetrol oral tablet) — Estetra. Estetrol is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors to provide estrogenic activity with a potentially improved safety profile.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Estetrol oral tablet TARGET Estetrol oral tablet Estetra phase 3 Selective estrogen receptor modulator (SERM) Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Toremifene; Anastrozole Toremifene; Anastrozole Peking Union Medical College Hospital marketed Selective estrogen receptor modulator (SERM) + aromatase inhibitor (AI) Estrogen receptor (ER); aromatase (CYP19A1)
Metformin plus clomiphene citrate Metformin plus clomiphene citrate University Magna Graecia marketed Combination therapy: biguanide + selective estrogen receptor modulator (SERM) Insulin signaling pathway (metformin); estrogen receptor (clomiphene citrate)
Low Dose Clomiphencitrat Low Dose Clomiphencitrat University Hospital, Basel, Switzerland marketed Selective estrogen receptor modulator (SERM) Estrogen receptor (ER-α and ER-β)
fenofibrate and tibolone fenofibrate and tibolone Keogh Institute for Medical Research marketed Fibrate + Selective Estrogen Receptor Modulator (SERM) PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone)
raloxifene HCI and alendronate Na raloxifene HCI and alendronate Na Eli Lilly and Company marketed Selective estrogen receptor modulator (SERM) + bisphosphonate combination Estrogen receptor (raloxifene); osteoclast farnesyl pyrophosphate synthase (alendronate)
Metformin + Clomiphene Metformin + Clomiphene University of Auckland, New Zealand marketed Combination therapy: biguanide + selective estrogen receptor modulator (SERM) Metformin: AMP-activated protein kinase (AMPK); Clomiphene: estrogen receptor (ER)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor modulator (SERM) class)

  1. University Hospital, Basel, Switzerland · 2 drugs in this class
  2. AstraZeneca · 2 drugs in this class
  3. Estetra · 1 drug in this class
  4. Fundació Privada Eugin · 1 drug in this class
  5. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
  6. National Taiwan University Hospital · 1 drug in this class
  7. Oregon Health and Science University · 1 drug in this class
  8. Samsung Medical Center · 1 drug in this class
  9. Shandong Suncadia Medicine Co., Ltd. · 1 drug in this class
  10. Sheba Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Estetrol oral tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/estetrol-oral-tablet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: